Effects of interleukin-23 on the activation of mucosal-associated invariant T cells from oral lichen planus. [PDF]
Wang F, Zhang XL, Yang JY, Zhou G.
europepmc +1 more source
ABSTRACT Doxorubicin‐induced cardiomyopathy (DIC) remains a dose‐limiting clinical challenge. This study reveals that cardiac vascular endothelial cells (CVECs) act as initial sensors of doxorubicin cardiotoxicity: circulating doxorubicin activates the cGAS‑STING pathway in CVECs, triggering NLRP3 inflammasome‑mediated pyroptosis and release of ...
Wang Jun +10 more
wiley +1 more source
Persistence and Long-Term Disease Control of Interleukin-17 Inhibitors and Interleukin-23 Inhibitors in Patients with Psoriasis: A Nationwide Cohort Study in Japan. [PDF]
Xu Y +8 more
europepmc +1 more source
Significance of Interleukin 23 in Systemic Lupus Patients: Relation to Disease Activity and Damage Indices. [PDF]
Haroon MM +4 more
europepmc +1 more source
A hybrid biomechanical–electromagnetic energy‐harvesting e‐skin is developed using a gelatin‐based outer matrix with a zwitterionic conductive inner layer. The e‐skin autonomously generates stable electrical stimulation from daily body motion and ambient electronics, enabling significantly enhanced wound healing bothin vitro and in vivo.
Syun‐Hong Chou +12 more
wiley +1 more source
A Genome-Wide Association Study Identifying Novel Genetic Markers of Response to Treatment with Interleukin-23 Inhibitors in Psoriasis. [PDF]
Zachari S +10 more
europepmc +1 more source
Induction of a colitogenic phenotype in Th1-like cells depends on interleukin-23 receptor signaling. [PDF]
Pawlak M +19 more
europepmc +1 more source
This study unveils an unrecognized pro‐inflammatory epitranscriptomic checkpoint in psoriasis. By installing m7G modifications on the 5′ UTR of Bdkrb1 mRNA, METTL1 enhances receptor stability to orchestrate keratinocyte‐driven neutrophil recruitment via p38 MAPK signaling.
Chang Zhang +10 more
wiley +1 more source
Case Report: Interleukin-23 blockade achieves sustained remission in Niemann-Pick type C-associated Crohn's disease refractory to anti-tumor necrosis factor therapy. [PDF]
Kakiuchi T +4 more
europepmc +1 more source

